Endocrine Abstracts

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have highly heterogeneous growth rates, yielding broad ranges of radiographic imaging intervals in standard guidelines, creating uncertainty for clinicians and patients. Chromogranin A (CgA) is released by GEP-NET cells and has been associated with increased tumor burden. However, clinical utility of CgA measurement has been limited by the lack of prospective validation studies and by different sensitivity for...

Background: We aimed to evaluate the added information provided by 68Ga-DOTATATE PET after two cycles of peptide receptor radionuclide therapy (PRRT) in patients with somatostatin receptor (SSTR)-expressing neuroendocrine tumors (NET).Methods: In this retrospective study, 105 patients (54 women and 51 men, 62.5&pm;10.5-year-old) with progressive NET treated with at least two cycles of 177Lu-DOTATATE were included. All patients had <...